Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Axsome Therapeutics, Inc. has 52.30M shares outstanding.

As of June 30, 2026, Axsome Therapeutics, Inc. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 269.73, indicating elevated leverage, while an interest coverage ratio of -35.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. posted a negative return on equity (ROE) of -245.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.35, reflecting losses generated across the asset base. The company generates approximately 15.69M in revenue per employee across its workforce of 864.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.87 indicates how many times Axsome Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. recorded 9.75M in income tax expense. The company reported a pretax loss of -3.34B and -3.35B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. generated 13.57B in revenue and converted that into -3.35B in net income, yielding earnings per share of -65.77. EBITDA reached -3.08B, while operating income came in at -3.19B.

As of June 30, 2026, Axsome Therapeutics, Inc. holds 5.59B in cash and equivalents against 3.93B in total debt, resulting in a net debt position of -2.30B. Total book value stands at 1.46B, with working capital of 3.43B providing operational flexibility.

Axsome Therapeutics, Inc. produced -1.25B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.23M in capital expenditures, free cash flow totaled -1.26B - equivalent to -24.69 per share.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. posted a gross margin of 93.24, reflecting its pricing power and cost economics. The operating margin of -23.55 and net profit margin of -24.68 provide insight into operational efficiency.